Filtered By:
Condition: ALS

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 644 results found since Jan 2013.

Neurological diseases and risk of suicide attempt: a case –control study
ConclusionNine out of ten chronic neurological diseases were associated with an increased risk of suicide attempt. These data must be considered for clinicians treating this vulnerable group of patients.
Source: Journal of Neurology - March 21, 2018 Category: Neurology Source Type: research

The Primitive Palmomental Reflex in Amyotrophic Lateral Sclerosis
Conclusion: We demonstrate a higher frequency of the PMR in ALS patients compared to NC or HC. Its expression increases with age, being higher in bulbar-onset patients. Given that the reflex circuit is located in the brain stem, its release due to inhibition might be associated to the presence of a cortico-bulbar tract dysfunction in ALS.Eur Neurol 2018;79:187 –191
Source: European Neurology - March 23, 2018 Category: Neurology Source Type: research

The role of inflammation in neurological disorders.
Abstract Traditionally neurological diseases have been classified, on the basis of their pathogenesis, into vascular, degenerative, inflammatory and traumatic diseases. Examples of the main inflammatory neurological diseases include multiple sclerosis, which is characterized by an immune-mediated immune response against myelin proteins, and meningoencephalitis, where the inflammatory response is triggered by infectious agents. However, recent evidence suggests a potential role of inflammatory mechanisms also in neurological conditions not usually categorized as inflammatory, such as Alzheimer's disease, Parkinson'...
Source: Current Pharmaceutical Design - March 27, 2018 Category: Drugs & Pharmacology Authors: Degan D, Ornello R, Tiseo C, Carolei A, Sacco S, Pistoia F Tags: Curr Pharm Des Source Type: research

Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD Dr. Ehlers is with Biogen in Cambridge, Massachusetts. Innov Clin Neurosci. 2018;15(3–4):15–16 Funding: No funding was received for the preparation of this article. Disclosures: Dr. Ehlers is an employee and shareholder at Biogen Inc. in Cambridge, Massachusetts. Prominent and expensive failures in Alzheimer’s disease therapies have led to a contagious belief system in some parts of the biopharma industry that neuroscience is just too hard, too risky, and too uncertain. But, might this belief system itself be a residual bias of the past? Close inspection reveals all the signs of a coming...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Commentary Current Issue Source Type: research

Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study
Dextromethorphan 20 mg / quinidine 10 mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based on phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety, and tolerability for PBA following stroke, dementia, or traumatic brain injury (TBI).
Source: PM and R - February 22, 2018 Category: Rehabilitation Authors: Flora M. Hammond, William Sauve, Fred Ledon, Charles Davis, Andrea E. Formella Tags: Original Research Source Type: research

FDA Lays the Smackdown on Illegal Stem Cell Clinics
FDA is cracking down on stem cell clinics that market unapproved products and don't meet good manufacturing practice requirements. On behalf of the agency, the Department of Justice filed two complaints in federal court this week seeking permanent injunctions against a Florida-based clinic and a California-based clinic.  “Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk. In some instances, patients have suffered serious and permanent harm after re...
Source: MDDI - May 10, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis.
Abstract Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease, and at present, therapies for ALS are limited. Estrogen is a potential therapeutic agent for ALS but has undesirable effects that might increase the risk of breast and uterine cancers or stroke. Raloxifene (Ral) has estrogenic properties but does not exhibit these adverse effects. However, the mechanism of Ral in ALS has not been studied. We thus investigated the effects of Ral in an NSC34 model of ALS that stably expresses the 25-kDa C-terminal fragment of TDP-43 (i.e., TDP-25 cells) and found that GPR30 (G protein-coup...
Source: Brain Research Bulletin - May 25, 2018 Category: Neurology Authors: Zhou F, Dong H, Liu Y, Yan L, Sun C, Hao P, Liu Y, Zhai J, Liu Y Tags: Brain Res Bull Source Type: research

AcuraStem receives fast-track SBIR grant
(AcuraStem, Inc.) AcuraStem, a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, 'AS2015', focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.
Source: EurekAlert! - Medicine and Health - June 18, 2018 Category: International Medicine & Public Health Source Type: news

Aquinnah Pharmaceuticals receives $3.4 million grant from NINDS to advance new therapies for ALS
(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Source: EurekAlert! - Biology - June 20, 2018 Category: Biology Source Type: news

New funding to UC Riverside to significantly boost cancer, ALS research
(University of California - Riverside) Maurizio Pellecchia at the University of California, Riverside has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. The first grant from the US-Egypt Science and Technology Joint Fund of the National Academy of Sciences, Engineering, and Medicine totals $190,000 for two years. The second is a nearly $2.3 million, five-year grant from the National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Cancer - June 21, 2018 Category: Cancer & Oncology Source Type: news

Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system.
Abstract Cannabinoid receptor CB2 (CB2R) is upregulated on activated microglia and astrocytes in the brain under inflammatory conditions and plays important roles in many neurological diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. The advent of positron emission tomography (PET) using CB2R radiotracers has enabled the visualization of CB2R distribution in vivo in animal models of central nervous system inflammation, however translation to humans has been less successful. Several novel CB2R radiotracers have been developed and evaluated to quantify microglial activation. ...
Source: Acta Pharmacologica Sinica - June 19, 2018 Category: Drugs & Pharmacology Authors: Ni R, Mu L, Ametamey S Tags: Acta Pharmacol Sin Source Type: research

Glossokinetic potential based tongue –machine ınterface for 1-D extraction using neural networks
This study may serve disabled people to control assistive devices in natural, unobtrusive, speedy and reliable manner. Moreover, it is expected that GKP-based TMI could be a collaboration channel for traditional electroencephalography (EEG)-based brain computer interfaces which have significant inadequacies arisen from the EEG signals.
Source: Biocybernetics and Biomedical Engineering - June 29, 2018 Category: Biomedical Engineering Source Type: research

Comparison of Premortem Magnetic Resonance Imaging and Postmortem Autopsy Findings of a Cortical Microinfarct
An 85-year-old woman diagnosed with amyotrophic lateral sclerosis died of pneumonia and was autopsied. Magnetic resonance imaging (MRI) performed 16days before death revealed an intracortical high-intensity lesion in her right temporal cortex on three-dimensional (3D)-double inversion recovery (DIR) and 3D-fluid-attenuated inversion recovery (FLAIR) images. Histopathological examination indicated a cortical microinfarct (CMI) juxtaposed to cerebral amyloid angiopathy. Recently, in vivo detection of CMIs using 3D-DIR and 3D-FLAIR on 3-tesla MRI has been reported, and postmortem MRI study confirmed the presence of CMIs.
Source: Journal of Stroke and Cerebrovascular Diseases - July 2, 2018 Category: Neurology Authors: Hidehiro Ishikawa, Yuichiro Ii, Atsushi Niwa, Akihiro Shindo, Ai Ito, Keita Matsuura, Ryogen Sasaki, Kenichiro Uno, Masayuki Maeda, Hidekazu Tomimoto Source Type: research

Glossokinetic potential based tongue–machine ınterface for 1-D extraction using neural networks
This study may serve disabled people to control assistive devices in natural, unobtrusive, speedy and reliable manner. Moreover, it is expected that GKP-based TMI could be a collaboration channel for traditional electroencephalography (EEG)-based brain computer interfaces which have significant inadequacies arisen from the EEG signals.
Source: Biocybernetics and Biomedical Engineering - July 5, 2018 Category: Biomedical Engineering Source Type: research